<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">642871</article-id><article-id pub-id-type="doi">10.26442/00403660.2025.08.203365</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The introduction into clinical practice of an algorithm for the diagnosis of liver steatosis in patients with viral pneumonia</article-title><trans-title-group xml:lang="ru"><trans-title>Внедрение в клиническую практику алгоритма диагностики стеатоза печени у пациентов с вирусной пневмонией</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8441-7396</contrib-id><contrib-id contrib-id-type="scopus">57218197799</contrib-id><contrib-id contrib-id-type="spin">5631-8691</contrib-id><name-alternatives><name xml:lang="en"><surname>Turankova</surname><given-names>Taisia A.</given-names></name><name xml:lang="ru"><surname>Туранкова</surname><given-names>Таисия Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>ассистент каф. терапии Института профессионального образования</p></bio><email>turankova_t_a@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5587-8860</contrib-id><contrib-id contrib-id-type="scopus">36941944600</contrib-id><contrib-id contrib-id-type="spin">5737-5472</contrib-id><name-alternatives><name xml:lang="en"><surname>Brazhnikov</surname><given-names>Alexey Yu.</given-names></name><name xml:lang="ru"><surname>Бражников</surname><given-names>Алексей Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. эпидемиологии и доказательной медицины Института общественного здоровья</p></bio><email>turankova_t_a@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-8688-7133</contrib-id><name-alternatives><name xml:lang="en"><surname>Moroz</surname><given-names>Nadezhda G.</given-names></name><name xml:lang="ru"><surname>Мороз</surname><given-names>Надежда Геннадьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>врач-рентгенолог рентгенологического отд-ния Университетской клинической больницы №4</p></bio><email>turankova_t_a@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-3536-2296</contrib-id><name-alternatives><name xml:lang="en"><surname>Mudrova</surname><given-names>Anastasia V.</given-names></name><name xml:lang="ru"><surname>Мудрова</surname><given-names>Анастасия Васильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>студентка Института клинической медицины им. Н.В. Склифосовского</p></bio><email>turankova_t_a@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5745-7605</contrib-id><contrib-id contrib-id-type="scopus">57196353031</contrib-id><contrib-id contrib-id-type="spin">3689-5602</contrib-id><name-alternatives><name xml:lang="en"><surname>Varganova</surname><given-names>Daria L.</given-names></name><name xml:lang="ru"><surname>Варганова</surname><given-names>Дарья Леонидовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, зав. отд-нием гастроэнтерологии</p></bio><email>turankova_t_a@staff.sechenov.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5031-9798</contrib-id><contrib-id contrib-id-type="scopus">57196355076</contrib-id><contrib-id contrib-id-type="spin">5052-9020</contrib-id><name-alternatives><name xml:lang="en"><surname>Pavlov</surname><given-names>Chavdar S.</given-names></name><name xml:lang="ru"><surname>Павлов</surname><given-names>Чавдар Савов</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. каф. терапии Института профессионального образования; вед. науч. сотр.</p></bio><email>turankova_t_a@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет им. И.М. Сеченова</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Ulyanovsk Regional Clinical Hospital</institution></aff><aff><institution xml:lang="ru">Ульяновская областная клиническая больница</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Botkin Moscow Multidisciplinary Research and Clinical Center</institution></aff><aff><institution xml:lang="ru">Московский многопрофильный научно-клинический центр им. С.П. Боткина</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-08-28" publication-format="electronic"><day>28</day><month>08</month><year>2025</year></pub-date><volume>97</volume><issue>8</issue><issue-title xml:lang="en">Treatment issues</issue-title><issue-title xml:lang="ru">Вопросы лечения</issue-title><fpage>704</fpage><lpage>710</lpage><history><date date-type="received" iso-8601-date="2024-12-12"><day>12</day><month>12</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-08-26"><day>26</day><month>08</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/642871">https://ter-arkhiv.ru/0040-3660/article/view/642871</self-uri><abstract xml:lang="en"><p><bold>Aim.</bold> To study the ability and significance of detecting liver steatosis during chest computed tomography (CT) in patients with viral pneumonia.</p> <p><bold>Materials and methods.</bold> A prospective cohort study included 100 patients over the age of 18 who were hospitalized with an established diagnosis of viral pneumonia. To CT detection significant liver steatosis (more than 33%), several approaches were used: liver density less than 40 HU; decrease in liver density by at least 10 HU less than the spleen; the ratio of decrease in liver density to the spleen is less than 0.9.</p> <p><bold>Results.</bold> According to CT data 2 groups were identified: 25 patients with existing liver steatosis and metabolically associated fatty liver disease, and 74 patients of the control group without signs of significant steatosis, оne patient was excluded due to alcohol abuse. There was a significant difference in the study of liver density (31.68 ± 10.67 and 54.44 ± 5.95; <italic>p</italic> &lt; 0.001), the ratio of decrease in liver density to spleen density (0.66 ± 0.22 and 1.16 ± 0.13; <italic>p</italic> &lt; 0.001), as well as a decrease in liver density relative to the spleen (16.30 ± 10.38 and -7.26 ± 6.10; <italic>p</italic> &lt; 0.001). In the steatosis group, a more severe course of pneumonia was noted (<italic>p</italic> = 0.041). The incidence of deterioration according to CT was comparable in both groups: 19 (76%) and 45 (60.8%); <italic>p</italic> = 0.169, although its severity was higher in the group with steatosis (<italic>p</italic> = 0.012). Patients from the steatosis group were significantly more often prescribed biological (88.0 and 39.19%; <italic>p</italic> &lt; 0.001) and antibacterial therapy (68.0 and 40.54%; <italic>p</italic> = 0.017).</p> <p><bold>Conclusion.</bold> The use of assessment of liver steatosis according to CT data simultaneously with the study of the underlying disease can become an important diagnostic step determining the prognosis of the course of the disease, as well as a tool for risk stratification in patients with metabolically associated fatty liver disease.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель.</bold> Изучить возможности и значение выявления стеатоза печени во время проведения компьютерной томографии (КТ) органов грудной клетки пациентам с вирусной пневмонией.</p> <p><bold>Материалы и методы.</bold> В когортное проспективное исследование включены 100 пациентов в возрасте старше 18 лет, госпитализированных с установленным диагнозом вирусной пневмонии. Для выявления значительного стеатоза печени (более 33%) по КТ использовалось несколько подходов: плотность печени – менее 40 HU, ослабление плотности печени по крайней мере на 10 HU меньше, чем у селезенки, отношение ослабления плотности печени к селезенке – менее 0,9.</p> <p><bold>Результаты.</bold> По данным КТ выделены 25 пациентов с имеющимся стеатозом печени и другими критериями метаболически ассоциированной жировой болезни печени и 74 пациента контрольной группы без признаков значительного стеатоза, 1 пациент исключен в связи со злоупотреблением алкоголем. Выявлена достоверная разница при изучении плотности печени (31,68 ± 10,67 и 54,44 ± 5,95; <italic>р</italic> &lt; 0,001), отношения уменьшения плотности печени к плотности селезенки (0,66 ± 0,22 и 1,16 ± 0,13; <italic>р</italic> &lt; 0,001), а также уменьшение плотности печени по отношению к селезенке (16,3 ± 10,38 и -7,26 ± 6,1; <italic>р</italic> &lt; 0,001). В группе стеатоза отмечено более тяжелое течение пневмонии (<italic>р</italic> = 0,041). Частота ухудшения состояния по данным КТ была сопоставима в обеих группах: 19 (76,0%) и 45 (60,8%); <italic>р</italic> = 0,169, хотя его тяжесть была выше в группе со стеатозом (<italic>р</italic> = 0,012). Пациентам из группы стеатоза значительно чаще назначали биологическую (88,0 и 39,19%; <italic>р</italic> &lt; 0.001) и антибактериальную терапию (68,0 и 40,54%; <italic>p</italic> = 0,017).</p> <p><bold>Заключение.</bold> Внедрение оценки степени стеатоза печени по данным КТ одновременно с изучением основного заболевания может стать важным диагностическим этапом, определяющим прогноз течения заболевания, а также инструментом стратификации риска у пациентов с метаболически ассоциированной жировой болезнью печени.</p></trans-abstract><kwd-group xml:lang="en"><kwd>liver steatosis</kwd><kwd>metabolically associated fatty liver disease</kwd><kwd>computed tomography</kwd><kwd>Hepatic Steatosis Index</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>стеатоз печени</kwd><kwd>метаболически ассоциированная жировая болезнь печени</kwd><kwd>компьютерная томография</kwd><kwd>индекс стеатоза печени</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Райхельсон К.Л., Маевская М.В., Жаркова М.С., и др. Жировая болезнь печени: новая номенклатура и ее адаптация в Российской Федерации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(2):35-44 [Raikhelson KL, Maevskaya MV, Zharkova MS, et al. Steatotic liver disease: New nomenclature and its localization in the Russian Federation. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(2):35-44 (in Russian)]. DOI:10.22416/1382-4376-2024-961</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Amini-Salehi E, Letafatkar N, Norouzi N, et al. Global prevalence of nonalcoholic fatty liver disease: an updated meta-analysis on 78 million population over 38 countries. Arch Med Res. 2024;55(6):103043. DOI:10.1016/j.arcmed.2024.103043</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-86. DOI:10.1097/HEP.0000000000000520</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Павлов Ч.С., Теплюк Д.А., Лазебник Л.Б., и др. Взгляд клинициста на преимущества и противоречия новой номенклатуры стеатозной болезни печени. Терапевтический архив. 2024;96(4):429-35 [Pavlov ChS, Teplyuk DA, Lazebnik LB, et al. The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(4):429-35 (in Russian)]. DOI:10.26442/00403660.2024.04.202747</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Tacke F, Horn P, Wai-Sun Wong V, et al. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. DOI:10.1016/j.jhep.2024.04.031</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Драпкина О.М., Мартынов А.И., Арутюнов Г.П., и др. Резолюция Форума экспертов «Новые терапевтические горизонты НАЖБП». Терапевтический архив. 2024;96(2):186-93 [Drapkina OM, Martynov AI, Arutyunov GP, et al. Resolution of the Expert Forum "New therapeutic horizons of NAFLD". Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(2):186-93 (in Russian)]. DOI:10.26442/00403660.2024.02.202648</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Bae JS, Lee DH, Suh KS, et al. Noninvasive assessment of hepatic steatosis using a pathologic reference standard: comparison of CT, MRI, and US-based techniques. Ultrasonography. 2022;41(2):344-54. DOI:10.14366/usg.21150</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kazi IN, Kuo L, Tsai E. Noninvasive methods for assessing liver fibrosis and steatosis. Gastroenterol Hepatol (N Y). 2024;20(1):21-9. PMID:38405045</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528-62. DOI:10.1016/j.eprac.2022.03.010</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol. 2024;81(3):492-542. DOI:10.1016/j.jhep.2024.04.031</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Farrell GC, McCullough AJ, Day CP. (Eds.) Non-alcoholic fatty liver disease: A practical guide. New York: Wiley Blackwell, 2013.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Chitturi S, Wong VW, Chan WK, et al. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease Guidelines 2017 – Part 2: Management and special groups. J Gastroenterol Hepatol. 2018;33(1):86-98. DOI:10.1111/jgh.13856</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Brunt EM. Nonalcoholic fatty liver disease: Pros and cons of histologic systems of evaluation. Int J Mol Sci. 2016;17(1):97. DOI:10.3390/ijms17010097</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Bozic D, Podrug K, Mikolasevic I, Grgurevic I. Ultrasound methods for the assessment of liver steatosis: A critical appraisal. Diagnostics (Basel). 2022;12(10):2287. DOI:10.3390/diagnostics12102287</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Cao YT, Xiang LL, Qi F, et al. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. EClinicalMedicine. 2022;51:101547. DOI:10.1016/j.eclinm.2022.101547</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Gu J, Liu S, Du S, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: A meta-analysis. Eur Radiol. 2019;29(7):3564-73. DOI:10.1007/s00330-019-06072-4</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Wang XM, Zhang XJ, Ma L. Diagnostic performance of magnetic resonance technology in detecting steatosis or fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Medicine (Baltimore). 2018;97(21):e10605. DOI:10.1097/MD.0000000000010605</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Jawahar A, Gonzalez B, Balasubramanian N, et al. Comparison of computed tomography hepatic steatosis criteria for identification of abnormal liver function and clinical risk factors, in incidentally noted fatty liver. Eur J Gastroenterol Hepatol. 2020;32(2):216-21. DOI:10.1097/MEG.0000000000001502</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Byun J, Lee SS, Sung YS, et al. CT indices for the diagnosis of hepatic steatosis using non-enhanced CT images: Development and validation of diagnostic cut-off values in a large cohort with pathological reference standard. Eur Radiol. 2019;29(8):4427-35. DOI:10.1007/s00330-018-5905-1</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Park HJ, Kim KW, Kwon HJ, et al. CT-based visual grading system for assessment of hepatic steatosis: Diagnostic performance and interobserver agreement. Hepatol Int. 2022;16(5):1075-84. DOI:10.1007/s12072-022-10373-0</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Guo Z, Blake GM, Li K, et al. Liver fat content measurement with quantitative CT validated against MRI proton density fat fraction: A prospective study of 400 healthy volunteers. Radiology. 2020;294(1):89-97. DOI:10.1148/radiol.2019190467</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Hu N, Yan G, Tang M, et al. CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease. Eur Radiol Exp. 2023;7(1):72. DOI:10.1186/s41747-023-00387-0</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Engelke K. Quantitative computed tomography – Current status and new developments. J Clin Densitom. 2017;20(3):309-21. DOI:10.1016/j.jocd.2017.06.017</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Starekova J, Hernando D, Pickhardt PJ, Reeder SB. Quantification of liver fat content with CT and MRI: State of the art. Radiology. 2021;301(2):250-62. DOI:10.1148/radiol.2021204288</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Jophlin LL, Singal AK, Bataller R, et al. ACG Clinical Guideline: Alcohol-associated liver disease. Am J Gastroenterol. 2024;119(1):30-54. DOI:10.14309/ajg.0000000000002572</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503-8. DOI:10.1016/j.dld.2009.08.002</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Lawrence DA, Oliva IB, Israel GM. Detection of hepatic steatosis on contrast-enhanced CT images: Diagnostic accuracy of identification of areas of presumed focal fatty sparing. AJR Am J Roentgenol. 2012;199(1):44-7. DOI:10.2214/AJR.11.7838</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Lebre MA, Vacavant A, Grand-Brochier M, et al. Automatic segmentation methods for liver and hepatic vessels from CT and MRI volumes, applied to the Couinaud scheme. Comput Biol Med. 2019;110:42-51. DOI:10.1016/j.compbiomed.2019.04.014</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Wong VW, Ekstedt M, Wong GL, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79(3): 842-52. DOI:10.1016/j.jhep.2023.04.036</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>DiStefano JK, Gerhard GS. NAFLD in normal weight individuals. Diabetol Metab Syndr. 2022;14(1):45. DOI:10.1186/s13098-022-00814-z</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Tan D, Chan KE, Wong ZY, et al. Global epidemiology of cirrhosis: Changing etiological basis and comparable burden of nonalcoholic steatohepatitis between males and females. Dig Dis. 2023;41(6):900-12. DOI:10.1159/000533946</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Chung J, Park HS, Kim YJ, et al. Association of Hepatic Steatosis Index with nonalcoholic fatty liver disease diagnosed by non-enhanced CT in a screening population. Diagnostics (Basel). 2021;11(12):2168. DOI:10.3390/diagnostics11122168</mixed-citation></ref></ref-list></back></article>
